Reported 2 days ago
Morgan Stanley has raised its price target for CG Oncology, Inc. (NASDAQ:CGON) to $56 from $52 while retaining an Overweight rating. The firm noted that despite recent approvals in the non-muscle invasive bladder cancer market, there remains ample opportunity for multiple competitors. CG Oncology's product, cretostimogene, distinguishes itself with favorable safety data and durability, suggesting strong potential in the market.
Source: YAHOO